Asset Details
Do you wish to reserve the book?
The emerging role of incretins and twincretins
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The emerging role of incretins and twincretins
Do you wish to request the book?
The emerging role of incretins and twincretins
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The emerging role of incretins and twincretins
2022
Overview
In 2021, clinical trials reported the promising effects of incretins and a new class of dual glucagon-like peptide 1–glucose-dependent insulinotropic peptide receptor agonists in preventing and treating type 2 diabetes mellitus and obesity. These ‘twincretins’ will transform the prevention of obesity and type 2 diabetes mellitus and the care of people with these conditions.Key advancesOnce weekly semaglutide, the most potent GLP1 receptor agonist, was safe and effective for treating obesity, achieving average weight loss of 15% among individuals without any form of diabetes mellitus4.In the SURPASS-1 trial, tirzepatide (a new dual GIP–GLP1 receptor agonist based on the native GIP sequence) was associated with up to 2% reduction in HbA1c and a dose-dependent reduction in body weight of 7–9 kg in patients with type 2 diabetes mellitus6.Tirzepatide was superior to semaglutide in head-to-head comparisons in reducing HbA1c and body weight, with a similar incidence of gastrointestinal adverse effects7.Tirzepatide was also superior to insulin degludec in reducing HbA1c and body weight, with a lower risk of hypoglycaemia8.
Publisher
Nature Publishing Group
